- Home
- CNR vs RLAY Comparison
CNR vs RLAY Comparison
Compare CNR & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNR | RLAY |
|---|---|---|
| Founded | 1864 | 2015 |
| Country | United States | United States |
| Employees | 4850 | N/A |
| Industry | Coal Mining | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.1B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CNR | RLAY |
|---|---|---|
| Price | $83.48 | $18.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $111.50 | $19.50 |
| AVG Volume (30 Days) | 530.7K | ★ 3.5M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.44% | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,355,000.00 |
| Revenue This Year | $7.26 | N/A |
| Revenue Next Year | $6.83 | $324.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.44 |
| 52 Week Low | $68.78 | $3.03 |
| 52 Week High | $114.80 | $20.79 |
Technical Indicators
Market Signals| Indicator | CNR | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 48.54 | 50.31 |
| Support Level | $82.29 | $6.67 |
| Resistance Level | $91.91 | $20.79 |
| Average True Range (ATR) | 2.65 | 1.20 |
| MACD | 0.59 | -0.28 |
| Stochastic Oscillator | 51.47 | 1.99 |
Price Performance
Historical ComparisonAbout CNR Core Natural Resources Inc.
Core Natural Resources Inc is a producer and exporter of metallurgical and thermal coal. The company owns and operates longwall mining operations in the nation and export terminals on the Eastern seaboard. The activities of the company involves mining of thermal coal, power generation, and other related activities.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.